Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bluebird Bio (NQ: BLUE )

0.4050 +0.0272 (+7.20%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bluebird Bio

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
Where bluebird bio Stands With Analysts
Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the follow... 
Via Benzinga
bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Cognition Therapeutics (NASDAQ:CGTX 
Via Benzinga
Mid-Day Market Update: Crude Oil Drops Over 5%; Society Pass Shares Jump
Midway through trading Monday, the Dow traded down 1.78% to 34,735.33 while the NASDAQ fell 1.43% to 14,952.69. The S&P also fell, dropping 1.59% to 4,547.26. The U.S. has the... 
Via Benzinga
38 Stocks Moving In Monday's Mid-Day Session
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares jumped 120.9% to $7.31 after the company reported addition to the Russell 2000 Index. Can-Fite BioPharma Ltd. (NYSE: CANF... 
Via Benzinga
Why Are Bluebird Bio Shares Trading Lower Today?
The FDA has placed a partial clinical hold on Bluebird bio Inc's (NASDAQ: BLUE) lovotibeglogene autotemcel (lovo-cel) gene therapy program for sickle cell... 
Via Benzinga
bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program
From bluebird bio, Inc.
Via Business Wire
Bluebird bio's Neurodegenerative Disease Gene Therapy Under Priority FDA Review, Despite Clinical Hold
The FDA has accepted for priority review Buebird bio Inc's (NASDAQ: BLUE) marketing application for elivaldogene autotemcel (eli-cel, Lenti-D) for cerebral... 
Via Benzinga
bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor
From bluebird bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Arena Pharmaceuticals (NASDAQ:ARNA) stock moved upwards by 91.22% to $95.5 during Monday's pre-market session. The company's market cap stands at $5.8... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, investor! With our return from the weekend comes a dive into the biggest pre-market stock movers for Monday! 
Via InvestorPlace
New Data At ASH21 Show Bluebird's Thalassemia Gene Therapy Potentially Curative One-Time Treatment
Bluebird Bio Inc (NASDAQ: BLUE) presented new results for betibeglogene autotemcel (beti-cel), investigational gene therapy for β-thalassemia (beta-thal) who... 
Via Benzinga
Bluebird Bio Posts Updated Data From Sickle Cell Gene Therapy Program
Bluebird bio Inc (NASDAQ: BLUE) announced updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel (lovo-cel; formerly LentiGlobin for SCD,... 
Via Benzinga
22 Stocks Moving in Monday's Pre-Market Session
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 32.6% to $3.58 in pre-market trading after gaining more than 14% on Friday. Foghorn Therapeutics Inc. (NASDAQ: FHTX) rose... 
Via Benzinga
New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Therapy Program To-Date Presented at ASH21 and Published in NEJM
From bluebird bio, Inc.
Via Business Wire
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple... 
Via Benzinga
Exposures Product Safety
New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for β-thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb Levels
From bluebird bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers iSpecimen (NASDAQ:ISPC) stock rose 31.09% to $6.45 during Monday's pre-market session. The company's market cap stands at $44.9 million. Provention Bio (... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, traders! We're getting right into the week with a breakdown of the biggest pre-market stock movers for Monday! 
Via InvestorPlace
Exposures Product Safety
Bluebird Bio's Thalassemia Gene Therapy Under Priority Review With FDA
The FDA has accepted Bluebird bio Inc's (NASDAQ: BLUE) marketing application for betibeglogene autotemcel (beti-cel) for β-thalassemia. The agency has... 
Via Benzinga
Exposures Product Safety
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
From bluebird bio, Inc.
Via Business Wire
64 Biggest Movers From Yesterday
Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares jumped 219% to close at $10.40 on Monday after the company announced the launch of its E-Boost portfolio of mobile... 
Via Benzinga
Why Bluebird Bio Stock Plunged Today
Two analysts downgraded the biotech stock. 
Via The Motley Fool
Market Rally Continues as Dow Nabs Intraday Highs
S&P 500 Index and Nasdaq Composite are sporting modest gains, with the Dow locking in another fresh intraday high. 
Via Talk Markets
Topics Stocks
Exposures US Equities
38 Stocks Moving In Monday's Mid-Day Session
Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares climbed 129.8% to $7.49 after the company announced the launch of its E-Boost portfolio of mobile Electric Vehicle... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers PetVivo Holdings (NASDAQ:PETV) s... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021
Upgrades For Nektar Therapeutics (NASDAQ: 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Chinook Therapeutics (NASDAQ:KDNY) shares increased by 28.75% to $15.76 during Friday's regular session. Trading volume for this security as of 12:30 EST is 1.... 
Via Benzinga
92 Biggest Movers From Friday
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the... 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.